Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Neuronetics, Inc. (STIM)

Neuronetics Q3 revenue rises 12.5% to $42.0 million; net loss narrows to $1.7 million

Positive Impact 4 of 5 earnings Written later

Neuronetics reported third-quarter 2026 total revenue of $42.0 million, up 12.5% from a year earlier, with the Greenbrook clinic network driving most of the growth. The net loss attributable to stockholders narrowed to $1.7 million, or $0.02 per share, from $9.0 million, or $0.13 per share, and the company raised the low end of its full-year gross margin outlook while lowering its operating expense forecast.

Key points

  • Q3 2026 total revenue was $42.0 million, up 12.5%; Greenbrook revenue rose 20.1% to $26.2 million.
  • Net loss attributable to stockholders was $1.7 million, or $0.02 per share, versus $9.0 million, or $0.13 per share, in Q3 2025.
  • Full-year 2026 revenue guidance is unchanged at $160 million to $164 million; gross margin guidance is now 49% to 50%, up from 48% to 50%.
  • Full-year 2026 operating expense guidance was lowered to $92.5 million to $95.5 million from $95 million to $100 million.

The filing

CompanyNeuronetics, Inc. (STIM)
Form8-K, current report
Filed with the SECNov 4, 2026, 7:55 AM ET
Accession number0001193125-26-446239

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.